Pheochromocytomas are an uncommon tumor of the adrenal gland, with characteristic clinical, and to a lesser degree, imaging features. The tumors are said to follow a 10% rule:
- ~10% are extra-adrenal
- ~10% are bilateral
- ~10% are malignant
- ~10% are found in children
- ~10% are familial
- ~10% are not associated with hypertension
- ~10% contain calcification
The estimated prevalence of pheochromocytomas in hypertensive adults is thought to range from 0.1 to 0.6%. The incidence in the general population is believed to be around 0.05% based on autopsy series 9.
The majority of cases are sporadic. In 5-10% of cases, a pheochromocytoma is a manifestation of an underlying condition including 1-4,6:
- multiple endocrine neoplasia type II (MEN II): both MEN IIa and MEN IIb
- account for 3% of all pheochromocytomas
- almost never extra-adrenal
- almost always bilateral 4
- von Hippel-Lindau disease
- von Recklinghausen disease (neurofibromatosis type I)
- Sturge-Weber syndrome
- Carney triad: for extra-adrenal pheochromocytoma
- tuberous sclerosis
- familial pheochromocytoma
It is a rare but classical cause of uncontrolled secondary hypertension, with a minority having superimposed paroxysmal hypertensive crises 11. Patients may also present with cardiac dysfunction (myocardial infarction, pulmonary edema) or neurological events (a severe headache, visual disturbance, hemorrhagic strokes) 5.
The first investigation in cases where pheochromocytoma is suspected is usually urinary catecholamines. When those results are positive, then imaging is performed to try and localize the tumor or tumors.
Pheochromocytomas are a type of paraganglioma. They are catecholamine-secreting tumors derived from chromaffin cells. They typically demonstrate a nesting (Zellballen) pattern on microscopy. This pattern is composed of well-defined clusters of tumor cells containing eosinophilic cytoplasm separated by a fibrovascular stroma. Various pathological scoring systems are in use (PASS, GAPP) to predict differentiation and likelihood of metastasis 15.
They most frequently arise from the chromaffin cells of the adrenal medulla.
Approximately 10% of all pheochromocytomas are not located in the adrenal glands. Extra-adrenal tumors are more likely to be malignant and metastasize 4.
As a general rule, tumors in the adrenal region tend to be large at presentation, usually >3 cm, with an average size of approximately 5 cm. When confined to the adrenal glands, and especially if suspected clinically, the diagnosis is readily made. Small extra-adrenal tumors can, however, be a challenge to find. Overall 98% of tumors are in the abdomen, and 90% are confined to the adrenal glands 6.
It is also important to note that it is not possible to distinguish malignant from benign pheochromocytomas merely on the direct appearance of the mass. Rather, the distinction is made on demonstrating evidence of direct tumor invasion into adjacent organs/structures or the presence of metastases 4.
Pheochromocytomas can have a variable appearance ranging from solid to mixed cystic and solid to cystic 9.
CT is the first imaging modality to be used, with an overall sensitivity of 89%. This is on account of 98% of tumors being located within the abdomen and 90% limited to the adrenal glands 6.
- usually large, heterogeneous masses with areas of necrosis and cystic change
- they typically enhance avidly 8
- may wash out similar to an adrenal adenoma, but they tend to have a greater enhancement in an arterial or portal venous contrast phase
- tend to enhance more on the portal venous phase than the arterial phase
- 110 HU of enhancement on the arterial phase is compatible with pheochromocytoma; hypervascular metastases could be considered in an appropriate setting
- up to 7% demonstrate areas of calcification 4
It should be noted that suspected cases of pheochromocytomas have been historically managed as a contraindication for iodinated contrast administration, as it could theoretically precipitate a hypertensive crisis. However, studies have shown no evidence to support this theory and nowadays most radiology non-ionic iodinated contrast media guidelines do not put pheochromocytomas as a contraindication 13,16.
MRI is the most sensitive modality for identification of pheochromocytomas and is particularly useful in cases of extra-adrenal location. The overall sensitivity is said to be 98% 6.
- slightly hypointense to the remainder of the adrenal
- if necrotic and/or hemorrhagic then the signal will be more heterogeneous
- markedly hyperintense (lightbulb sign): this is a helpful feature
- ~ 1/3 do not have marked T2 hyperintensity 18
- areas of necrosis/hemorrhage/calcification will alter the signal
- markedly hyperintense (lightbulb sign): this is a helpful feature
- in-phase/out-of-phase: no signal loss on out-of-phase imaging (pheochromocytomas do not contain a large amount of intracellular lipid) 12
T1 C+ (Gd)
- heterogeneous enhancement
- enhancement is prolonged, persisting for as long as 50 minutes 4
Some agents can be used to attempt to image pheochromocytomas, and are especially useful in trying to locate an extra-adrenal tumor (when CT of the abdomen is negative) or metastatic deposits. Unfortunately, these agents are not very specific for pheochromocytomas and have a limited spatial resolution, usually requiring the tumor to be >1 cm in diameter.
Octreotide (Somatostatin) scans
Over 70% of tumors express somatostatin receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an intravenous infusion. Unfortunately, the kidney also has somatostatin receptors, as do areas of inflammation, mammary glands, liver, spleen, bowel, gallbladder, thyroid gland and salivary glands. As such interpretation can be difficult 5.
Octreotide is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly) 123I-Tyr3-DTPA 5.
I-123 MIBG (metaiodobenzylguanidine)
I-123 MIBG uptake in an adrenal nodule is strong supporting evidence for a pheochromocytoma. Overall sensitivity is approximately 80% 6. However, as many neuroendocrine tumors demonstrate uptake with MIBG, it is not as specific for pheochromocytoma outside of the adrenal.
18F-Dopa PET is thought to be highly sensitive according to initial results 3. Galium-68 DOTATATE PET/CT imaging has also been advocated due to their higher lesion to background tissue contrast and high specificity for pheochromocytoma 14.
18F-FDOPA (6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine)-based PET/CT imaging can also be a useful tool in diagnosis 17.
Treatment and prognosis
Definitive treatment is surgical, and if complete resection is achieved, without metastases, then surgery is curative, and hypertension usually resolves.
Preoperative medical management is essential in reducing the risk of intraoperative hypertensive crises and typically consists of the non-competitive alpha-adrenergic blockade (e.g. phenoxybenzamine). Later, but never before 7-10 days of alpha blockade, a beta-blocker may need to be added to control tachycardia or some arrhythmias 5,6.
Metastases from malignant pheochromocytomas are typical to the lung, bone and liver 4.
When located in the adrenal gland, the differential is essentially that of an adrenal tumor and includes:
- adrenal adenoma: also washes out, but <120 HU on an arterial or portal venous contrast phase
- adrenal carcinoma
- adrenal metastasis(es)
In large tumors, especially if malignant, differentiating them from renal cell carcinomas can be difficult, especially on CT images.
- clinical suspicion is almost always present before imaging: secondary hypertension and positive urinary catecholamines
- usually large and heterogeneous adrenal masses, with cystic and necrotic components
- vivid enhancement of arterial/portal venous phase: >110-120 HU
- 1. Ros PR, Mortele KJ. CT and MRI of the abdomen and pelvis, a teaching file. Lippincott Williams & Wilkins. (2006) ISBN:0781772370. Read it at Google Books - Find it at Amazon
- 2. Kumar V, Abbas AK, Fausto N et-al. Robbins and Cotran pathologic basis of disease. W B Saunders Co. (2005) ISBN:0721601871. Read it at Google Books - Find it at Amazon
- 3. Hoegerle S, Nitzsche E, Altehoefer C et-al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002;222 (2): 507-12. doi:10.1148/radiol.2222010622 - Pubmed citation
- 4. Reiser MF. Magnetic Resonance Tomography. Springer Verlag. (2007) ISBN:354029354X. Read it at Google Books - Find it at Amazon
- 5. Pacak K, Eisenhofer G, Lenders JW. Pheochromocytoma, Diagnosis, Localization, and Treatment. Wiley-Blackwell. (2007) ISBN:1405149507. Read it at Google Books - Find it at Amazon
- 6. Blake MA, Boland GW. Adrenal Imaging. Humana Pr Inc. (2009) ISBN:193411586X. Read it at Google Books - Find it at Amazon
- 7. Tsirlin A, Oo Y, Sharma R et-al. Pheochromocytoma: a review. Maturitas. 2014;77 (3): 229-38. doi:10.1016/j.maturitas.2013.12.009 - Pubmed citation
- 8. Blake MA, Kalra MK, Maher MM et-al. Pheochromocytoma: an imaging chameleon. Radiographics. 2004;24 Suppl 1 (suppl_1): S87-99. doi:10.1148/rg.24si045506 - Pubmed citation
- 9. Leung K, Stamm M, Raja A et-al. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200 (2): 370-8. doi:10.2214/AJR.12.9126 - Pubmed citation
- 10. Northcutt BG, Raman SP, Long C et-al. MDCT of adrenal masses: Can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?. AJR Am J Roentgenol. 2013;201 (4): 834-9. doi:10.2214/AJR.12.9753 - Pubmed citation
- 11. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol. Metab. Clin. North Am. 2011;40 (2): 295-311, vii. doi:10.1016/j.ecl.2011.02.002 - Free text at pubmed - Pubmed citation
- 12. Elsayes KM, Mukundan G, Narra VR et-al. Adrenal masses: mr imaging features with pathologic correlation. Radiographics. 2004;24 Suppl 1 (suppl 1): S73-86. Radiographics (full text) - doi:10.1148/rg.24si045514 - Pubmed citation
- 13. Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188 (4): 970-4. doi:10.2214/AJR.06.0827 - Pubmed citation
- 14. Chian A. Chang, David A. Pattison, Richard W. Tothill, Grace Kong, Tim J. Akhurst, Rodney J. Hicks, Michael S. Hofman. 68 Ga-DOTATATE and 18 F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. (2016) Cancer Imaging. 16 (1): 22. doi:10.1186/s40644-016-0084-2 - Pubmed
- 15. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. (2014) Endocrine-related cancer. 21 (3): 405-14. doi:10.1530/ERC-13-0494 - Pubmed
- 16. Baid SK, Lai EW, Wesley RA, Ling A, Timmers HJ, Adams KT, Kozupa A, Pacak K. Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. (2009) Annals of internal medicine. 150 (1): 27-32. Pubmed
- 17. Santhanam P et.al. Role of (18) F-FDOPA PET/CT Imaging in Endocrinology. (2014) Clinical endocrinology. doi:10.1111/cen.12566 - Pubmed
- 18. Gurinder Nandra, Oliver Duxbury, Pawan Patel, Jaymin H. Patel, Nirav Patel, Ioannis Vlahos. Technical and Interpretive Pitfalls in Adrenal Imaging. (2020) RadioGraphics. 40 (4): 1041-1060. doi:10.1148/rg.2020190080 - Pubmed
Related Radiopaedia articles
- adrenal gland anatomy
- adrenal adenoma
- adrenal metastasis
- adrenal cortical hyperplasia
- adrenal cortical carcinoma
- adrenal granulomatous disease
- adrenal myelolipoma
- adrenal hemorrhage
- adrenal abscess
- adrenal hemangioma
- adrenal cyst
- adrenal lymphangioma
- adrenal haemangiosarcoma
- adrenal lymphoma
- extramedullary hematopoiesis in adrenal gland
- tumors of the adrenal gland
- Management of Incidental Adrenal Masses: ACR White Paper
- differential diagnoses